Nabriva's pneumonia drug succeeds in late-stage trial, shares soar

Trader pointing

Nabriva Therapeutics plc (NBRV - Free Report) announced results from a phase III study where lefamulin demonstrated non-inferiority to Bayer AG's (BAYRY - Free Report) Avelox in treating patients with community-acquired bacterial pneumonia ("CABP"). RBC Capital Markets set a $22.00 price target on shares of Nabriva Therapeutics AG and gave the company a buy rating in a report on Tuesday, December 20th. Nabriva Therapeutics AG has a consensus rating of Buy and an average price target of $18.75.

After a recent spot-check, Nabriva Therapeutics plc (NASDAQ:NBRV)'s ATR is 1.19.

The highest price NBRV stock touched in the last 12 month was $14.1 and the lowest price it hit in the same period was $3.52.

In case of Revenue Estimates, 6 analysts have provided their consensus Average Revenue Estimates for Nabriva Therapeutics AG as 1.15 Million. Analyst fixed "buy" recommendation and a $20.00 price target for The corporation.

09/18/2017 - Nabriva Therapeutics AG had its "outperform" rating reiterated by analysts at Leerink Swann.

While looking at the Stock's Performance, Nabriva Therapeutics AG now shows a Weekly Performance of 0.68%, where Monthly Performance is 0.45%, Quarterly performance is -3.59%, 6 Months performance is -22.87% and yearly performance percentage is 19.54%.

Nabriva Therapeutics AG (NBRV) has a Return on Assets of 0 percent, Return on Investment of -70.3 percent and a Return on Equity of 0 percent. They now have a United States dollars 16 price target on the stock.

In the last earnings report the EPS was $-11.49 and is expected to be $-2.28 for the current year with 26,838,000 shares now outstanding. The 50 day moving average went up by +13.72% whereas the 200 day average was up by +0.80%. Stock's distance from 52 week High is -30.43% and the distance from 52 week Low is 151.99%. Insiders sold a total of 279,000 shares of company stock valued at $2,870,869 in the last three months. The Monday move followed previous stock weakness, including a almost 8% decline after Seltzer's announcement. Nationwide Fund Advisors boosted its position in Nabriva Therapeutics AG by 4.6% in the 2nd quarter. FT Options LLC increased its stake in Nabriva Therapeutics AG by 43.1% in the fourth quarter. Almanack Investment Partners LLC. lifted its stake in Nabriva Therapeutics AG by 482.2% in the second quarter. FCF is an important factor as it enables a company to pursue opportunities that boost shareholder value. Finally, Wellington Management Group LLP lifted its position in shares of Nabriva Therapeutics AG by 9.9% during the 1st quarter. Hillhouse Capital Management, Ltd. controls 686,400 shares with a value of $7,193,000.

The company's website shows that a mid-stage study of the drug for acute skin and skin structure infections has also been completed. After this trade, the executive now has 2,591,396 stocks in the company, assessed at roughly $28,401,700.16. Institutional investors and hedge funds own 68.56% of the company's stock. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. It is also developing BC-7013, a topical pleuromutilin product candidate, which has completed a Phase 1 clinical trial.



Other news